195 related articles for article (PubMed ID: 10607427)
1. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels.
Koo GC; Blake JT; Shah K; Staruch MJ; Dumont F; Wunderler D; Sanchez M; McManus OB; Sirotina-Meisher A; Fischer P; Boltz RC; Goetz MA; Baker R; Bao J; Kayser F; Rupprecht KM; Parsons WH; Tong XC; Ita IE; Pivnichny J; Vincent S; Cunningham P; Hora D; Feeney W; Kaczorowski G
Cell Immunol; 1999 Nov; 197(2):99-107. PubMed ID: 10607427
[TBL] [Abstract][Full Text] [Related]
2. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3.
Felix JP; Bugianesi RM; Schmalhofer WA; Borris R; Goetz MA; Hensens OD; Bao JM; Kayser F; Parsons WH; Rupprecht K; Garcia ML; Kaczorowski GJ; Slaughter RS
Biochemistry; 1999 Apr; 38(16):4922-30. PubMed ID: 10213593
[TBL] [Abstract][Full Text] [Related]
3. Potent Kv1.3 inhibitors from correolide-modification of the C18 position.
Bao J; Miao S; Kayser F; Kotliar AJ; Baker RK; Doss GA; Felix JP; Bugianesi RM; Slaughter RS; Kaczorowski GJ; Garcia ML; Ha SN; Castonguay L; Koo GC; Shah K; Springer MS; Staruch MJ; Parsons WH; Rupprecht KM
Bioorg Med Chem Lett; 2005 Jan; 15(2):447-51. PubMed ID: 15603971
[TBL] [Abstract][Full Text] [Related]
4. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity.
Baell JB; Gable RW; Harvey AJ; Toovey N; Herzog T; Hänsel W; Wulff H
J Med Chem; 2004 Apr; 47(9):2326-36. PubMed ID: 15084131
[TBL] [Abstract][Full Text] [Related]
5. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo.
Koo GC; Blake JT; Talento A; Nguyen M; Lin S; Sirotina A; Shah K; Mulvany K; Hora D; Cunningham P; Wunderler DL; McManus OB; Slaughter R; Bugianesi R; Felix J; Garcia M; Williamson J; Kaczorowski G; Sigal NH; Springer MS; Feeney W
J Immunol; 1997 Jun; 158(11):5120-8. PubMed ID: 9164927
[TBL] [Abstract][Full Text] [Related]
6. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
[TBL] [Abstract][Full Text] [Related]
7. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
Bagdány M; Batista CV; Valdez-Cruz NA; Somodi S; Rodriguez de la Vega RC; Licea AF; Varga Z; Gáspár R; Possani LD; Panyi G
Mol Pharmacol; 2005 Apr; 67(4):1034-44. PubMed ID: 15615696
[TBL] [Abstract][Full Text] [Related]
8. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation.
Beeton C; Barbaria J; Giraud P; Devaux J; Benoliel AM; Gola M; Sabatier JM; Bernard D; Crest M; Béraud E
J Immunol; 2001 Jan; 166(2):936-44. PubMed ID: 11145670
[TBL] [Abstract][Full Text] [Related]
9. Potassium channels as therapeutic targets for autoimmune disorders.
Wulff H; Beeton C; Chandy KG
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
[TBL] [Abstract][Full Text] [Related]
10. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators.
Vennekamp J; Wulff H; Beeton C; Calabresi PA; Grissmer S; Hänsel W; Chandy KG
Mol Pharmacol; 2004 Jun; 65(6):1364-74. PubMed ID: 15155830
[TBL] [Abstract][Full Text] [Related]
11. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.
Peukert S; Brendel J; Pirard B; Brüggemann A; Below P; Kleemann HW; Hemmerle H; Schmidt W
J Med Chem; 2003 Feb; 46(4):486-98. PubMed ID: 12570371
[TBL] [Abstract][Full Text] [Related]
12. Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3.
Butenschön I; Möller K; Hänsel W
J Med Chem; 2001 Apr; 44(8):1249-56. PubMed ID: 11312924
[TBL] [Abstract][Full Text] [Related]
13. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
Nguyen A; Kath JC; Hanson DC; Biggers MS; Canniff PC; Donovan CB; Mather RJ; Bruns MJ; Rauer H; Aiyar J; Lepple-Wienhues A; Gutman GA; Grissmer S; Cahalan MD; Chandy KG
Mol Pharmacol; 1996 Dec; 50(6):1672-9. PubMed ID: 8967992
[TBL] [Abstract][Full Text] [Related]
14. Modulation of voltage-gated potassium channels in human T lymphocytes by extracellular glutamate.
Poulopoulou C; Markakis I; Davaki P; Nikolaou C; Poulopoulos A; Raptis E; Vassilopoulos D
Mol Pharmacol; 2005 Mar; 67(3):856-67. PubMed ID: 15718225
[TBL] [Abstract][Full Text] [Related]
15. Ion channels and lymphocyte activation.
Panyi G; Varga Z; Gáspár R
Immunol Lett; 2004 Mar; 92(1-2):55-66. PubMed ID: 15081528
[TBL] [Abstract][Full Text] [Related]
16. Ion channels in T cells: from molecular pharmacology to therapy.
Krasznai Z
Arch Immunol Ther Exp (Warsz); 2005; 53(2):127-35. PubMed ID: 15928581
[TBL] [Abstract][Full Text] [Related]
17. Heteromultimeric Kv1 channels contribute to myogenic control of arterial diameter.
Plane F; Johnson R; Kerr P; Wiehler W; Thorneloe K; Ishii K; Chen T; Cole W
Circ Res; 2005 Feb; 96(2):216-24. PubMed ID: 15618540
[TBL] [Abstract][Full Text] [Related]
18. Tityustoxin-K(alpha) blockade of the voltage-gated potassium channel Kv1.3.
Rodrigues AR; Arantes EC; Monje F; Stühmer W; Varanda WA
Br J Pharmacol; 2003 Jul; 139(6):1180-6. PubMed ID: 12871837
[TBL] [Abstract][Full Text] [Related]
19. 3-Alkyl- and 3-aryl-7H-furo[3,2-g]chromen-7-ones as blockers of the voltage-gated potassium channel Kv1.3.
Wernekenschnieder A; Körner P; Hänsel W
Pharmazie; 2004 Apr; 59(4):319-20. PubMed ID: 15125582
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of voltage-gated and calcium-activated potassium channels.
Kaczorowski GJ; Garcia ML
Curr Opin Chem Biol; 1999 Aug; 3(4):448-58. PubMed ID: 10419851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
